Incidence of pneumococcal and all-cause pneumonia in adults in Catalonia following the implementation of universal pneumococcal vaccination in children: 2015-2016 vs. 2017-2018.

INTRODUCTION

To analyze the incidence of pneumonia in adults following public funding of the 13-valent pneumococcal conjugate vaccine (PCV13) for children in Catalonia.

METHODS

Two cohorts were analyzed: 2,025,730 individuals aged ≥50 years in 2015-2016 (pre-funding) and 2,059,645 in 2017-2018 (post-funding). Hospitalizations for pneumococcal pneumonia (PP) and all-cause pneumonia (ACP) were identified through the CMBD database across 68 Catalonian hospitals. Incidence rate ratios (IRR) between periods were estimated.

RESULTS

PP incidence increased from 83.6/100,000 (2015-2016) to 90.7/100,000 (2017-2018) (IRR: 1.09; 95%CI: 1.03-1.14), while ACP decreased slightly from 617.9/100,000 to 609.7/100,000 (IRR: 0.99; 95%CI: 0.97-1.00). ACP reductions were significant in individuals aged 65-79, those with chronic lung disease, and men. PP increased significantly in those aged>80 years.

CONCLUSION

Adult hospitalized pneumonia incidence did not significantly decrease in the two years following PCV13 public funding for children.